

Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD —
Management of Non-Small Cell Lung Cancer with an EGFR Mutation

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III ADAURA study evaluated what systemic therapy regimen for localized non-small cell lung cancer (NSCLC) with an EGFR mutation?**
 - Neoadjuvant osimertinib monotherapy
 - Adjuvant osimertinib monotherapy**
 - Perioperative osimertinib plus durvalumab
- 2. Patritumab deruxtecan targets which of the following biomarkers?**
 - EGFR
 - HER2
 - HER3**
 - None of the above
- 3. According to data from the Phase III TROPION-Lung01 trial, datopotamab deruxtecan appears to be more efficacious for patients with which type of previously treated advanced NSCLC?**
 - Squamous
 - Nonsquamous**
 - Neither of the above; patients with either histology benefitted equally
- 4. Which of the following front-line therapies conferred the greatest progression-free survival (PFS) benefit for patients with advanced NSCLC with an EGFR mutation in the Phase III FLAURA2 trial?**
 - Osimertinib monotherapy
 - Osimertinib and chemotherapy**
 - PFS was equivalent for either therapy
- 5. Amivantamab is FDA approved in combination with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic NSCLC with which of the following EGFR mutations?**
 - Exon 18 mutations
 - Exon 19 mutations
 - Exon 20 mutations**
 - Amivantamab is FDA approved for all of the above mutations